Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase

Pharmacotherapy

Volumn 30, Issue 1, 2010, Pages 111-

  Vilay, A Mary ^a   Mueller, Bruce A ^a   Haines, Hilary ^b   Alten, Jeffery A ^c   Askenazi, David J ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Heerskink School of Medicine   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Acute kidney failure; Adolescent; Methotrexate; Renal replacement therapy; glutamyl hydrolase

Indexed keywords

ALBUMIN; CARBOXYPEPTIDASE G2; CREATININE; METHOTREXATE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ALBUMIN DIALYSIS; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BRAIN DISEASE; CANCER CHEMOTHERAPY; CASE REPORT; CONTINUOUS EXTRACORPOREAL THERAPY; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMODIALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE BLOOD LEVEL; DIALYSATE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG REMOVAL; EFFLUENT RATE; FEMALE; FLOW RATE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GLOMERULUS FILTRATION RATE; HEALTH CARE ACCESS; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; LIVER FAILURE; OLIGURIA; OSTEOSARCOMA; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PHARMACOLOGICAL PROCEDURES; PLASMA CONCENTRATION-TIME CURVE; REBOUND; SATURATION COEFFICIENT; SINGLE PASS ALBUMIN DIALYSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING; URINE VOLUME;

EID: 84899061982     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1592/phco.30.1.111     Document Type: Article

References (21)

1. Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 2009;63:599-604.
2. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100:2222-32.
3. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11:694-703.
4. Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005;92:480-7.
5. Huffman DH, Wan SH, Azarnoff DL, Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973;14:572-9.
6. Leme PR, Creaven PJ, Allen LM, Berman M. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep 1975;59:811-17.
7. Evans WE, Stewart CF, Hutson PR, et al. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia. Drug Intell Clin Pharm 1982;16: 839-42.
8. Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res 1965;25:1018-24.
9. Wan SH, Huffman DH, Azarnoff DL. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974;34:3487-91.
10. Molina R, Fabian C, Cowley B. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med 1987;82:350-2.
11. Thomson AH, Daly M, Knepil J, Harden P, Symonds P. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. Cancer Chemother Pharmacol 1996;38:566-70.
12. Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS, Quigley R. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002;17:825-9.
13. Jambou P, Levraut J, Favier C, Ichai C, Milano G, Grimaud D. Removal of methotrexate by continuous venovenous hemodiafiltration. Contrib Nephrol 1995;116:48-52.
14. Pasko DA, Grio M, Thomas S, Mottes T, Brophy PD. Methotrexate transmembrane clearance during albumin based continuous venovenous hemodialysis [abstract]. Blood Purif 2005;23:165.
15. Askenazi DJ, Goldstein SL, Chang IF, Elenberg E, Feig DI. Management of a severe carbamazepine overdose using albumin-enhanced continuous venovenous hemodialysis. Pediatrics 2004;113:406-9.
16. Karvellas CJ, Bagshaw SM, McDermid RC, Stollery DE, Gibney RT. Acetaminophen-induced acute liver failure treated with single-pass albumin dialysis: report of a case. Int J Artif Organs 2008;31:450-5.
17. Pichon N, Francois B, Chevreuil C, Gaulier JM. Albumin dialysis: a new therapeutic alternative for severe diltiazem intoxication. Clin Toxicol (Phila) 2006;44:195-6.
18. Bunchman TE, Maxvold NJ, Brophy PD. Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation. Am J Kidney Dis 2003;42:1248-52.
19. Churchwell MD, Pasko DA, Smoyer WE, Mueller BA. Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis. Nephrol Dial Transplant 2009;24:231-8.
20. Schwartz S, Borner K, Müller K, et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007;12:1299-308.
21. Roberts DM, Buckley NA. Pharmacokinetics consideration in clinical toxicology: clinical applications. Clin Pharmacokinet 2007;46:897-939.